Presented Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones
Priced Offering of $5 Million Convertible Redeemable Preferred Stock through a Private Placement
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Presented Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones
Priced Offering of $5 Million Convertible Redeemable Preferred Stock through a Private Placement
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| ADXS | 0.1951 | +0.1550 | +386.53% |
| Ayala Pharmaceuticals Inc | |||